R
Recursion Pharma
A clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery
At a glance
- Status
- Listed
- Listing
- IPO 2021
Open roles
Recursion Pharma in the Salt Lake City ecosystem
The Recursion Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
- CNCentral Texas Angel Network
- BFBill & Melinda Gates Foundation
Series A11 investors entered at this stage
DCVC
AME Cloud Ventures- SVSahsen Ventures
Felicis- EVEPIC Ventures
- NTNat Turner
Lux Capital
Amplify Partners- WIWild Basin Investments
David Beyer
Obvious Ventures
Series B and later19 investors entered at this stage
Casdin Capital- PMPlatinum Asset Management
- IHIntermountain Healthcare
Two Sigma Ventures- ACAdvantage Capital
- SBSamsara BioCapital
Mubadala Capital- UUUniversity of Utah
- LBLeaps by Bayer
- CMCatalio Capital Management
Kinnevik- TITwo Sigma Investments
- IVIntermountain Ventures
Baillie Gifford- INInvus
- LMLaurion Capital Management
Menlo Ventures
CRV- STScottish Mortgage Investment Trust
Source: Dealroom Talent Intelligence.
Alumni founders
Former Recursion Pharma employees who went on to found companies, sorted by Dealroom signal score.
RBRetro BiosciencesEst. 2020
Joe Betts-LacroixUnited States
EBEnveda BiosciencesEst. 2019
Viswa ColluruUnited States
NONoetikEst. 2022
Ron Alfa, MD, PhDUnited States
ACAchiraEst. 2024
Zavain DarUnited States
David KartchnerUnited StatesPatents
117 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Recursion Pharma was the backer or acquirer, 2020–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
5 deals across Recursion Pharma's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Recursion Pharma deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Recursion Pharma's portfolio, mapped.
See Recursion Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Recursion aligns with FDA on registrational Phase 3 design for FAP candidate REC-4881
Recursion posts positive Phase 2 FAP data and options first drug candidate to Sanofi
Recursion raises $200M in oversubscribed offering, extends runway to 2029